Guard Therapeutics announces final result of rights issue

The final result of the rights issue that was announced on 20 October 2021 and where the subscription period ended on 29 November 2021 (the "Rights Issue") in Guard Therapeutics International AB (publ) ("Guard Therapeutics" or the "Company"), shows that the Rights Issue was subscribed to approximately 41 percent. The remaining approximately 59 percent of the Rights Issue was subscribed for by Rutger Arnhult, through M2 Asset Management AB, and Jan Ståhlberg in accordance with given declarations of intention to subscribe. As a result of the Rights Issue, Guard Therapeutics will receive proceeds amounting to approximately SEK 128 million before issue costs.

The final result shows that 37,071,300 shares, corresponding to approximately 40.6 percent of the shares in the Rights Issue, were subscribed for by the exercise of subscription rights. In addition, 369,929 shares were subscribed for without subscription rights, corresponding to approximately 0.4 percent of the shares in the Rights Issue. Thus, the Rights Issue was subscribed to approximately 41.0 percent. Rutger Arnhult, through M2 Asset Management AB, and Jan Ståhlberg have subscribed for the remaining approximately 59.0 percent of the shares, meaning that they subscribed for approximately 29.5 percent of the shares, respectively.

As a result of the Rights Issue, Guard Therapeutics will receive proceeds amounting to approximately SEK 128 million before deduction of issue costs. Through the Rights Issue, Guard Therapeutics' share capital will increase by SEK 1,825,704.60, from SEK 5,035,910.30 to SEK 6,861,614.90 and the total number of shares will increase by 91,285,230. After the Rights Issue, the total number of shares in Guard Therapeutics will amount to 343,080,745.

Allotment of shares subscribed for without subscription rights have been made in accordance with the principles outlined in the EU Growth Prospectus that was published by the Company on 10 November 2021 (the "Prospectus"). In the event of allotment, the payment notice is estimated to be sent out around 3 December 2021. Subscribed and allotted shares must be paid for in cash in accordance with the instructions in the payment notice. Nominee-registered shareholders will receive notice of allotment in accordance with the procedures of the nominee. Only those who have been allotted shares will be notified.

The last day for trading in paid subscribed shares (BTA) is 10 December 2021. The new shares are expected to start trading on Nasdaq First North Growth Market on or about 16 December 2021.

Advisers
Danske Bank A/S, Danmark, Sverige Filial is financial advisor and Setterwalls Advokatbyrå AB is legal advisor to Guard Therapeutics in connection with the Rights Issue.

IMPORTANT INFORMATION
The information in this press release does not contain or constitute an offer to acquire, subscribe or otherwise trade in shares or other securities in Guard Therapeutics. No action has been taken and measures will not be taken to permit a public offering in any jurisdictions other than Sweden. Any invitation to the persons concerned to subscribe for shares in Guard Therapeutics has only been made through the Prospectus and the supplementary prospectus that was published by the Company on 24 November 2021 and which is part of, and shall in all respects be read together with, the Prospectus. The Prospectus has been approved and registered by the Swedish Financial Supervisory Authority and has been published on the Company's website (www.guardtherapeutics.com). The approval of the Prospectus by the Swedish Financial Supervisory Authority shall not be regarded as an approval of the shares or any other securities. This release is however not a prospectus in accordance to the definition in the Prospectus Regulation (EU) 2017/1129 ("Prospectus Regulation") and this announcement does not identify or suggest, or purport to identify or suggest, the risks (direct or indirect) that may be associated with an investment in shares or other securities in Guard Therapeutics. In order for investors to fully understand the potential risks and benefits associated with a decision to participate in the Rights Issue, any investment decision should only be made based on the information in the Prospectus. Thus, investors are encouraged to review the Prospectus in its entirety.

The information in this press release may not be released, distributed or published, directly or indirectly, in or into the United States of America, Australia, Canada, Hong Kong, Japan, New Zealand, Singapore, South Africa or any other jurisdiction in which such action would be unlawful or would require registration or any other measures than those required by Swedish law. Actions in violation of these restrictions may constitute a violation of applicable securities laws. No shares or other securities in Guard Therapeutics have been registered, and no shares or other securities will be registered, under the United States Securities Act of 1933, as amended (the "Securities Act") or the securities legislation of any state or other jurisdiction in the United States of America and no shares or other securities may be offered, sold or otherwise transferred, directly or indirectly, in or into the United States of America, except under an available exemption from, or in a transaction not subject to, the registration requirements under the Securities Act and in compliance with the securities legislation in the relevant state or any other jurisdiction of the United States of America.

Within the European Economic Area ("EEA"), no public offering of shares or other securities ("Securities") is made in other countries than Sweden. In other member states of the EU, such an offering of Securities may only be made in accordance with the Prospectus Regulation. In other member states of the EEA which have implemented the Prospectus Regulation in its national legislation, any offer of Securities may only be made in accordance with an applicable exemption in the Prospectus Regulation and/or in accordance with an applicable exemption under a relevant national implementation measure. In other member states of the EEA which have not implemented the Prospectus Regulation in its national legislation, any offer of Securities may only be made in accordance with an applicable exemption under national law.

In the United Kingdom, this document and any other materials in relation to the securities described herein is only being distributed to, and is only directed at, and any investment or investment activity to which this document relates is available only to, and will be engaged in only with, "qualified investors" (within the meaning of the United Kingdom version of the EU Prospectus Regulation (2017/1129/ EU) which is part of United Kingdom law by virtue of the European Union (Withdrawal) Act 2018) who are (i) persons having professional experience in matters relating to investments who fall within the definition of "investment professionals" in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order"); (ii) high net worth entities etc. falling within Article 49(2)(a) to (d) of the Order; or (iii) such other persons to whom such investment or investment activity may lawfully be made available under the Order (all such persons together being referred to as "relevant persons"). In the United Kingdom, any investment or investment activity to which this communication relates is available only to, and will be engaged in only with, relevant persons. Persons who are not relevant persons should not take any action on the basis of this press release and should not act or rely on it.

This press release may contain forward-looking statements which reflect the Company's current view on future events and financial and operational development. Words such as "intend", "expect", "anticipate", "may", "believe", "plan", "estimate" and other expressions which imply indications or predictions of future development or trends, and which are not based on historical facts, are intended to identify forward-looking statements. Forward-looking statements inherently involve both known and unknown risks and uncertainties as they depend on future events and circumstances. Forward-looking statements do not guarantee future results or development and the actual outcome could differ materially from the forward-looking statements.

The English text is an unofficial translation of the original Swedish text. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.

For further information, please contact:

Tobias Agervald, CEO
Telephone: +46 8 670 65 51
E-mail: [email protected]  

About Guard Therapeutics

Guard Therapeutics is a pharmaceutical company that identifies and develops new therapies for diseases with a great medical need for more effective treatments. The company's clinical investigational drug ROSgard is being developed as a protective treatment against acute kidney injury with an initial focus on patients undergoing heart surgery. Guard Therapeutics is listed on Nasdaq First North Growth Market Stockholm.

Certified Adviser is Svensk Kapitalmarknadsgranskning AB, tel. +46 11 32 30 732, [email protected]

Guard Therapeutics får godkännande från Läkemedelsverket för klinisk studie av RMC-035 inom njurtransplantation

Guard Therapeutics meddelar idag att bolaget har erhållit godkännande från Läkemedelsverket för att starta en klinisk fas 1b-studie med läkemedelskandidaten RMC-035 (ROSgard) i patienter som genomgår njurtransplantation. Genom den planerade studien breddar därmed bolaget den kliniska utvecklingen av RMC-035 till ytterligare ett indikationsområde där behovet av njurskyddande behandling är stort. Studien kommer att inkludera upp till 12 individer och utförs för att dokumentera läkemedelskandidatens farmakokinetik i den aktuella patientgruppen. Bolaget väntas kunna presentera kompletta studieresultat under det första halvåret 2023.


Kommuniké från årsstämma i Guard Therapeutics International AB (publ) den 12 maj 2022

Idag, den 12 maj 2022, hölls årsstämma i Guard Therapeutics International AB (publ). Mot bakgrund av den fortsatta spridningen av Coronaviruset genomfördes årsstämman enbart genom förhandsröstning (poströstning), med stöd av tillfälliga lagregler. Nedan följer en sammanfattning av de beslut som fattades. Samtliga beslut fattades med erforderlig majoritet.


Guard Therapeutics offentliggör delårsrapport för januari-mars 2022

Delårsrapporten finns tillgänglig i sin helhet som bifogat dokument samt på bolagets hemsida www.guardtherapeutics.com.


Guard Therapeutics rekryterar ny Head of CMC

Guard Therapeutics meddelar idag att bolaget har utsett Torbjörn Larsson till Head of CMC (Chemistry, Manufacturing and Controls). Torbjörn Larsson tar plats i ledningsgruppen och kommer att rapportera direkt till vd.


Guard Therapeutics publicerar årsredovisning 2021

Guard Therapeutics AB (publ) meddelar idag att bolaget publicerar årsredovisningen för verksamhetsåret 2021.


Guard Therapeutics lämnar fördjupad information om klinisk fas 2-studie

Guard Therapeutics lämnar idag utökad information om planen för bolagets globala, kliniska fas 2-studie av ROSgard i patienter som genomgår öppen hjärtkirurgi med ytterligare riskfaktorer för att utveckla njurskador. Studien syftar till att utvärdera den njurskyddande behandlingseffekten av ROSgard och väntas ge ett omfattande dataunderlag inför den fortsatta kliniska utvecklingen inklusive utformningen av en efterföljande registreringsgrundande studie. Fas 2-studien går under benämningen AKITA och förväntas generera blindade interimsresultat under första kvartalet 2023 och topline-resultat under senare delen av 2023. Guard Therapeutics vd, Tobias Agervald, presenterar studieupplägget i en videointervju som finns tillgänglig via länk längre ned i detta pressmeddelande.


Första patienten har doserats i Guard Therapeutics kliniska fas 2-studie av ROSgard

Guard Therapeutics meddelar idag att den första patienten har doserats i bolagets globala kliniska fas 2-studie av ROSgard. Studien utförs i patienter som genomgår öppen hjärtkirurgi och därmed löper risk att utveckla akuta njurskador. Resultaten förväntas ge avgörande information om läkemedelskandidatens behandlingseffekt hos denna patientgrupp och även vägleda utformningen av en efterföljande registreringsgrundande studie.


First patient has been dosed in Guard Therapeutics' Phase 2 clinical trial of ROSgard

Guard Therapeutics today announces that the first patient has been dosed in the company's global phase 2 clinical trial of ROSgard. The study is conducted in patients who undergo open heart surgery and thus are at risk of developing acute kidney injury. The results are expected to provide conclusive information on the treatment effect of the investigational drug in this patient group and to guide the design of a subsequent pivotal study.


KALLELSE TILL ÅRSSTÄMMA I GUARD THERAPEUTICS INTERNATIONAL AB (PUBL)

Aktieägarna i Guard Therapeutics International AB (publ), org. nr 556755-3226 ("Guard Therapeutics"), kallas härmed till årsstämma torsdagen den 12 maj 2022.


Guard Therapeutics offentliggör bokslutskommuniké januari-december 202

Bokslutskommunikén finns tillgänglig i sin helhet som bifogat dokument samt på bolagets hemsida www.guardtherapeutics.com.

Nedan följer en kort sammanfattning av bokslutskommunikén.


Guard Therapeutics erhåller godkännande att expandera den globala kliniska fas 2-studien av ROSgard till Kanada

Guard Therapeutics meddelar idag att läkemedelsmyndigheten Health Canada har godkänt en ansökan om att inkludera patienter i Kanada i bolagets omfattande kliniska fas 2-studie av ROSgard, en läkemedelskandidat som utvecklas för prevention och behandling av akuta njurskador. Denna globala studie planeras att genomföras i Europa och Nordamerika och är sedan tidigare godkänd av läkemedelsmyndigheten i Tyskland.


Följ oss

Om beQuoted

beQuoted publicerar nyheter, analyser och pressmeddelanden för investerare och journalister. Viktiga företagshändelser bevakas av vår egen nyhetsredaktion och vidaredistribueras i ledande finansiella medier.

Vi uppdaterar även nyhetsrum, Investor Relations och IR-webbplatser för företag som vill utveckla sina relationer med finansmarknaden.

Kontakta oss

beQuoted AB
Nybrogatan 34
Box 5216
102 45 Stockholm

08-692 21 90

Om beQuoted